CN102105153B - Sglt2抑制剂的医药用途和含该抑制剂的组合物 - Google Patents

Sglt2抑制剂的医药用途和含该抑制剂的组合物 Download PDF

Info

Publication number
CN102105153B
CN102105153B CN200980128978.3A CN200980128978A CN102105153B CN 102105153 B CN102105153 B CN 102105153B CN 200980128978 A CN200980128978 A CN 200980128978A CN 102105153 B CN102105153 B CN 102105153B
Authority
CN
China
Prior art keywords
inhibitor
sglt2
uric acid
hyperuricemia
dapagliflozin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980128978.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102105153A (zh
Inventor
B·R·莱斯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102105153A publication Critical patent/CN102105153A/zh
Application granted granted Critical
Publication of CN102105153B publication Critical patent/CN102105153B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
CN200980128978.3A 2008-05-22 2009-05-15 Sglt2抑制剂的医药用途和含该抑制剂的组合物 Expired - Fee Related CN102105153B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5535208P 2008-05-22 2008-05-22
US61/055352 2008-05-22
PCT/US2009/044156 WO2009143020A1 (en) 2008-05-22 2009-05-15 Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same

Publications (2)

Publication Number Publication Date
CN102105153A CN102105153A (zh) 2011-06-22
CN102105153B true CN102105153B (zh) 2014-03-05

Family

ID=40810833

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980128978.3A Expired - Fee Related CN102105153B (zh) 2008-05-22 2009-05-15 Sglt2抑制剂的医药用途和含该抑制剂的组合物

Country Status (9)

Country Link
US (1) US8791077B2 (enExample)
EP (2) EP2291189B1 (enExample)
JP (2) JP5820269B2 (enExample)
CN (1) CN102105153B (enExample)
BR (1) BRPI0913129A2 (enExample)
CA (1) CA2725047A1 (enExample)
ES (1) ES2526930T3 (enExample)
MX (1) MX2010012656A (enExample)
WO (1) WO2009143020A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
ES2669184T3 (es) 2010-06-16 2018-05-24 Takeda Pharmaceuticals U.S.A., Inc. Nuevas formas de dosificación de liberación modificada de inhibidor de xantina oxidorreductasa o inhibidores de xantina oxidasa
US20140093563A1 (en) * 2011-06-13 2014-04-03 Ranbaxy Laboratories Limited Febuxostat compositions
CN104066430A (zh) * 2012-01-27 2014-09-24 帝人制药株式会社 糖尿病的治疗药
EP2968235B1 (en) * 2013-03-15 2017-09-13 Janssen Pharmaceutica NV Combination of canagliflozin and probenecid for the treatment of hyperuricemia
EP2981269B9 (en) 2013-04-04 2023-12-06 Boehringer Ingelheim Vetmedica GmbH Treatment of metabolic disorders in equine animals
ES2859905T3 (es) 2013-12-17 2021-10-04 Boehringer Ingelheim Vetmedica Gmbh Inhibidores de SGLT2 para el tratamiento de trastornos metabólicos en animales felinos
KR20220097538A (ko) 2014-01-23 2022-07-07 베링거잉겔하임베트메디카게엠베하 개과 동물에서 대사 장애의 치료
PL3125882T3 (pl) 2014-04-01 2020-10-19 Boehringer Ingelheim Vetmedica Gmbh Leczenie zaburzeń metabolicznych u zwierząt koniowatych
DK3197429T3 (da) 2014-09-25 2024-08-26 Boehringer Ingelheim Vetmedica Gmbh Kombinationsbehandling med sglt2-hæmmere og dopaminagonister til forebyggelse af metaboliske lidelser af dyr i hestefamilien
HUE069575T2 (hu) 2015-08-27 2025-03-28 Boehringer Ingelheim Vetmedica Gmbh Folyékony gyógyászati készítmények, amelyek SGLT-2-inhibitorokat tartalmaznak
KR101863604B1 (ko) * 2016-04-08 2018-06-04 한국 한의학 연구원 익지 추출물을 유효성분으로 함유하는 고요산혈증 또는 고요산혈증 관련 대사 장애의 예방, 개선 또는 치료용 조성물
WO2018167589A1 (en) 2017-03-16 2018-09-20 Inventia Healthcare Private Limited Pharmaceutical composition comprising dapagliflozin
WO2019087239A1 (ja) * 2017-10-30 2019-05-09 合同会社カルナヘルスサポート 腎症治療剤
JPWO2019092770A1 (ja) * 2017-11-07 2019-11-14 合同会社カルナヘルスサポート 網膜疾患治療剤
BR112021006002A2 (pt) * 2018-10-01 2021-06-29 Astrazeneca Ab composições para a redução de ácido úrico sérico
KR20210100677A (ko) 2018-12-06 2021-08-17 아쓰로시 테라퓨틱스, 인크. 통풍 또는 고뇨산혈증의 치료 또는 예방을 위한 화합물의 결정형
CA3121624A1 (en) 2018-12-06 2020-06-11 Arthrosi Therapeutics, Inc. Methods for treating or preventing gout or hyperuricemia
WO2020178821A1 (en) * 2019-03-03 2020-09-10 Algatechnologies Ltd. Compositions comprising algae powder and uses thereof
JP6831961B2 (ja) * 2019-10-23 2021-02-24 株式会社カルナヘルスサポート 網膜疾患治療剤
UY38969A (es) 2019-11-28 2021-05-31 Boehringer Ingelheim Vetmedica Gmbh Uso de inhibidores de sglt-2 en el secado de mamíferos no humanos
JP2023529691A (ja) * 2020-06-10 2023-07-11 アースローシ セラピューティクス，インク． 慢性腎疾患を処置または防止するための方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1695665A (zh) * 2004-11-29 2005-11-16 成都中汇制药有限公司 一种治疗痛风的药物
WO2007093610A1 (en) * 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20080004336A1 (en) * 2006-06-28 2008-01-03 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346094A (en) * 1980-09-22 1982-08-24 Eli Lilly And Company 3-Aryl-5-isothiazolecarboxylic acids and related compounds used to lower uric acid levels
CA2102591C (en) 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
JP2814950B2 (ja) 1994-05-11 1998-10-27 田辺製薬株式会社 血糖降下剤
US5830873A (en) 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
JP3034192B2 (ja) 1995-11-07 2000-04-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3065235B2 (ja) 1995-11-07 2000-07-17 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
JP3006513B2 (ja) 1995-11-07 2000-02-07 田辺製薬株式会社 医薬組成物
JP3059088B2 (ja) 1995-11-07 2000-07-04 田辺製薬株式会社 プロピオフェノン誘導体およびその製法
DK0850948T3 (da) 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenonderivater og fremgangsmåde til fremstilling deraf
JPH10245391A (ja) 1997-03-03 1998-09-14 Dainippon Ink & Chem Inc ７−グリコシロキシベンゾピラン誘導体を有効成分とする糖尿病治療剤
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
ES2337127T3 (es) 2000-11-02 2010-04-21 Ajinomoto Co., Inc. Nuevos derivados de pirazol y remedios contra la diabetes que los contienen.
WO2002068439A1 (fr) * 2001-02-26 2002-09-06 Kissei Pharmaceutical Co., Ltd. Derives de glycopyranosyloxypyrazole et utilisation medicinale de ceux-ci
WO2002068440A1 (en) 2001-02-27 2002-09-06 Kissei Pharmaceutical Co., Ltd. Glycopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
JP4292570B2 (ja) 2001-04-27 2009-07-08 味の素株式会社 Ｎ−置換ピラゾール−ｏ−グリコシド誘導体及びそれらを含有する糖尿病治療薬
JP4464128B2 (ja) 2001-06-20 2010-05-19 パーデュー リサーチ ファウンデーション 血液指標の体外光学測定用の部位照射加圧帯
KR100945455B1 (ko) 2002-03-22 2010-03-05 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시벤질 벤젠 유도체의 결정
ES2567571T3 (es) 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
JPWO2004089967A1 (ja) * 2003-04-01 2006-07-06 大正製薬株式会社 ヘテロアリール５−チオ−β−Ｄ−グルコピラノシド誘導体及びそれを含有する糖尿病治療薬
US7439232B2 (en) 2003-04-01 2008-10-21 Taisho Pharmaceutical Co., Ltd. Heteroaryl 5-thio-β-D-glucopyranoside derivatives and therapeutic agents for diabetes containing the same
JP2004359630A (ja) 2003-06-06 2004-12-24 Yamanouchi Pharmaceut Co Ltd ジフルオロジフェニルメタン誘導体及びその塩
US20050027128A1 (en) * 2003-07-30 2005-02-03 Robbins Timothy A. Substituted thiazoles
EP2514756B1 (en) 2003-08-01 2014-12-17 Mitsubishi Tanabe Pharma Corporation Novel compounds having inhibitory activity against sodium-dependant glucose transporter
UA86042C2 (en) 2003-08-01 2009-03-25 Янссен Фармацевтика Н.В. Substituted indazole-o-glucosides
US7375090B2 (en) 2003-08-26 2008-05-20 Boehringer Ingelheim International Gmbh Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof
WO2005063788A1 (ja) * 2003-12-26 2005-07-14 Kissei Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体及びその医薬用途
PL1730131T3 (pl) 2004-03-16 2012-10-31 Boehringer Ingelheim Int Glukopiranozylo-podstawione pochodne benzenu, środki lecznicze zawierające te związki, ich zastosowanie i sposób ich wytwarzania
CA2560005A1 (en) 2004-03-31 2005-10-13 Kissei Pharmaceutical Co., Ltd. Phenol derivative, medicinal composition containing the same, and medicinal use thereof
JP2005350375A (ja) * 2004-06-09 2005-12-22 Kikkoman Corp 血中尿酸値低下剤
US7393836B2 (en) 2004-07-06 2008-07-01 Boehringer Ingelheim International Gmbh D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture
DE102004034690A1 (de) 2004-07-17 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methyliden-D-xylopyranosyl-und Oxo-D-xylopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW200606129A (en) 2004-07-26 2006-02-16 Chugai Pharmaceutical Co Ltd Novel cyclohexane derivative, its prodrug, its salt and diabetic therapeutic agent containing the same
WO2006010557A1 (de) 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2006018150A1 (de) 2004-08-11 2006-02-23 Boehringer Ingelheim International Gmbh D-xylopyranosyl-phenyl-substituierte cyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
JP2006117651A (ja) 2004-09-27 2006-05-11 Taisho Pharmaceut Co Ltd Ｓｇｌｔ２の活性阻害剤
CA2581922A1 (en) 2004-09-29 2006-04-06 Kissei Pharmaceutical Co., Ltd. 1-(.beta.-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof
DE102004048388A1 (de) 2004-10-01 2006-04-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE102004058449A1 (de) 2004-12-03 2006-06-14 Merck Patent Gmbh Tetrahydropyranderivate
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
ATE484499T1 (de) 2005-08-30 2010-10-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte benzyl-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
BRPI0711949A2 (pt) 2006-05-19 2012-01-17 Taisho Pharmaceutical Co., Ltd. composto c-fenil glicitol
WO2007140191A2 (en) * 2006-05-23 2007-12-06 Theracos, Inc. Glucose transport inhibitors and methods of use
AR063627A1 (es) * 2006-11-09 2009-02-04 Boehringer Ingelheim Int Terapia combinada con inhibidores de sgl t-2 y sus composiciones farmaceuticas
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
US8603989B2 (en) * 2008-05-22 2013-12-10 Bristol-Myers Squibb Company Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1695665A (zh) * 2004-11-29 2005-11-16 成都中汇制药有限公司 一种治疗痛风的药物
WO2007093610A1 (en) * 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
US20080004336A1 (en) * 2006-06-28 2008-01-03 Bristol-Myers Squibb Company Crystal structures of sglt2 inhibitors and processes for preparing same

Also Published As

Publication number Publication date
MX2010012656A (es) 2010-12-20
BRPI0913129A2 (pt) 2016-01-05
EP2291189A1 (en) 2011-03-09
ES2526930T3 (es) 2015-01-16
EP2291189B1 (en) 2014-10-01
US8791077B2 (en) 2014-07-29
JP2014205700A (ja) 2014-10-30
US20110065658A1 (en) 2011-03-17
JP2011520965A (ja) 2011-07-21
CN102105153A (zh) 2011-06-22
WO2009143020A1 (en) 2009-11-26
CA2725047A1 (en) 2009-11-26
EP2668953A1 (en) 2013-12-04
JP5820269B2 (ja) 2015-11-24

Similar Documents

Publication Publication Date Title
CN102105153B (zh) Sglt2抑制剂的医药用途和含该抑制剂的组合物
JP5337040B2 (ja) Ｓｇｌｔ−２インヒビターとの組み合わせ治療及びそれらの医薬組成物
US8551957B2 (en) Pharmaceutical composition comprising a glucopyranosyl-substituted benzene derivate
US8088743B2 (en) Methods for treating obesity employing an SGLT2 inhibitor
JP5835598B2 (ja) 神経弛緩剤で治療されている患者において代謝性障害を治療するためのｓｇｌｔ−２阻害剤
CN101784286A (zh) 包含sglt2抑制剂与dpp-iv抑制剂的药物组合物
BRPI1008560B1 (pt) Composição farmacêutica compreendendo um inibidor de sglt2, um inibidor de dpp-iv e opcionalmente um outro agente antidiabético e usos dos mesmos
TW200838548A (en) Pharmaceutical composition comprising a pyrazole-O-glucoside derivative
US8603989B2 (en) Method for treating and preventing kidney stones employing an SGLT2 inhibitor and composition containing same
US8518895B2 (en) Method for treating hyponatremia employing an SGLT2 inhibitor and composition containing same
KR20250113341A (ko) 나트륨 포도당 운반체-2 저해제 및 안지오텐신 ⅱ 수용체 차단제를 함유하는 비만 예방 또는 치료용 약학적 조성물
HK1134653A (en) Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
HK1145442A (en) Pharmaceutical composition comprising a sglt2 inhibitor in combination with a dpp-iv inhibitor
HK1161544A (en) Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
NZ711659A (en) Therapeutic uses of empagliflozin

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: ASTRAZENECA AB

Free format text: FORMER OWNER: SQUIBB BRISTOL MYERS CO.

Effective date: 20140617

C41 Transfer of patent application or patent right or utility model
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: American New York

Patentee after: BRISTOL-MYERS SQUIBB Co.

Address before: New jersey, USA

Patentee before: BRISTOL-MYERS SQUIBB Co.

TR01 Transfer of patent right

Effective date of registration: 20140617

Address after: Swedish Sodertalje

Patentee after: ASTRAZENECA AB

Address before: American New York

Patentee before: BRISTOL-MYERS SQUIBB Co.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140305

Termination date: 20170515

CF01 Termination of patent right due to non-payment of annual fee